BMC Medicine· 2026Q1
Intranasal delivery of BMP2/6 recombinant proteins attenuating Parkinsonian pathology-induced neuronal degeneration
- 0citations
- Q1SCImago
- 2026year
Short summary
Intranasal delivery of BMP2/6 recombinant proteins significantly slowed dopaminergic neuron degeneration in Parkinson's disease mouse models, improving motor function.
AI-generated from the title and abstract; the full text is not read.
Key points
- Intranasal BMP2/6 recombinant proteins were tested in Parkinson's disease (PD) models.
- In vitro, BMP2/6 enhanced neural stem cell survival and differentiation.
- In vivo, BMP2/6 treatment significantly reduced dopaminergic neuron degeneration in PD mice.
- Motor function, assessed by rotarod and apomorphine tests, showed improvement in treated mice.
AI-generated from the title and abstract; the full text is not read.
Abstract
Parkinson’s disease (PD) is characterized by the progressive degeneration of nigrostriatal dopaminergic neurons (DAn), which highlights the importance of neuroprotective strategies that target critical pathways for DAn maintenance. The BMP2/6-SMAD1 signaling axis plays a pivotal role in the development and functional maturation of nigrostriatal dopaminergic neuronal circuits, suggesting the therapeutic potential of BMP2/6 for DAn in PD. In vitro, A53T-α-synuclein-overexpressing neural stem cells obtained by lentiviral transduction were treated with recombinant BMP2/6. In vivo, mice with 6-hydroxydopamine- and α-synuclein preformed fibril lesions received intranasal delivery of mouse BMP2/6 recombinant proteins. Recombinant BMP2/6 treatment improved the viability, proliferation, and differentiation capacity of A53T‑α‑synuclein‑overexpressing neural stem cells, suggesting that BMP2/6 may exert protective effects on the survival and differentiation of DAn. In vivo, intranasal delivery of mouse BMP2/6 recombinant proteins to PD mice significantly delayed DAn neurodegeneration. There was also improved motor function in rotarod tests and apomorphine-induced rotation tests. These findings suggest that BMP2/6 may reduce DAn death in PD models, indicating a potential role for early neuroprotection.
The authors' abstract, as published at the source. BMC Medicine, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Pharmaceutical Science
Pharmaceutical SciencePharmacology, Toxicology and Pharmaceutics